MA49374A - Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine - Google Patents
Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanineInfo
- Publication number
- MA49374A MA49374A MA049374A MA49374A MA49374A MA 49374 A MA49374 A MA 49374A MA 049374 A MA049374 A MA 049374A MA 49374 A MA49374 A MA 49374A MA 49374 A MA49374 A MA 49374A
- Authority
- MA
- Morocco
- Prior art keywords
- vanine
- inhibitors
- compounds used
- heteroaromatic compounds
- heteroaromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518106P | 2017-06-12 | 2017-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49374A true MA49374A (fr) | 2021-04-21 |
Family
ID=62631060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049374A MA49374A (fr) | 2017-06-12 | 2018-06-08 | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine |
Country Status (23)
Country | Link |
---|---|
US (2) | US10364255B2 (fr) |
EP (1) | EP3638680B1 (fr) |
JP (1) | JP6880243B2 (fr) |
KR (1) | KR102607934B1 (fr) |
CN (1) | CN110770242B (fr) |
AR (1) | AR112086A1 (fr) |
AU (1) | AU2018285131B2 (fr) |
BR (1) | BR112019021703A2 (fr) |
CA (1) | CA3066946A1 (fr) |
CL (1) | CL2019003515A1 (fr) |
CO (1) | CO2019013823A2 (fr) |
DK (1) | DK3638680T3 (fr) |
EA (1) | EA039223B1 (fr) |
ES (1) | ES2927021T3 (fr) |
HU (1) | HUE060597T2 (fr) |
IL (1) | IL271104B (fr) |
MA (1) | MA49374A (fr) |
MX (1) | MX2019014876A (fr) |
PE (1) | PE20200340A1 (fr) |
PH (1) | PH12019502693A1 (fr) |
PL (1) | PL3638680T3 (fr) |
TW (1) | TW201920196A (fr) |
WO (1) | WO2018228934A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3638680T3 (pl) * | 2017-06-12 | 2022-12-19 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
SG11202101749VA (en) * | 2018-08-28 | 2021-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as vanin inhibitors |
AU2019391279A1 (en) | 2018-12-03 | 2021-05-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
WO2021174024A1 (fr) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Méthodes de traitement de la colite auto-immune iatrogène |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1680415B1 (fr) * | 2003-10-09 | 2008-12-31 | Abbott Laboratories | Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese |
WO2016193844A1 (fr) * | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1 |
CN109476645A (zh) * | 2016-07-14 | 2019-03-15 | 辉瑞大药厂 | 作为vanin-1酶抑制剂的新的嘧啶甲酰胺 |
PL3638680T3 (pl) * | 2017-06-12 | 2022-12-19 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
-
2018
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 BR BR112019021703-7A patent/BR112019021703A2/pt unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/fr active Active
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 MX MX2019014876A patent/MX2019014876A/es unknown
- 2018-06-08 CA CA3066946A patent/CA3066946A1/fr active Pending
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active IP Right Grant
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/fr unknown
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TW201920196A/zh unknown
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR112086A1 (es) | 2019-09-18 |
PH12019502693A1 (en) | 2020-07-13 |
CN110770242B (zh) | 2022-08-19 |
US20190263828A1 (en) | 2019-08-29 |
AU2018285131B2 (en) | 2021-11-11 |
PL3638680T3 (pl) | 2022-12-19 |
JP6880243B2 (ja) | 2021-06-02 |
CA3066946A1 (fr) | 2018-12-20 |
PE20200340A1 (es) | 2020-02-14 |
CO2019013823A2 (es) | 2020-01-17 |
DK3638680T3 (da) | 2022-09-05 |
MX2019014876A (es) | 2020-02-13 |
AU2018285131A1 (en) | 2019-10-31 |
WO2018228934A1 (fr) | 2018-12-20 |
IL271104B (en) | 2022-03-01 |
CL2019003515A1 (es) | 2020-06-19 |
US10364255B2 (en) | 2019-07-30 |
EP3638680A1 (fr) | 2020-04-22 |
TW201920196A (zh) | 2019-06-01 |
KR20200013718A (ko) | 2020-02-07 |
EA039223B1 (ru) | 2021-12-20 |
EP3638680B1 (fr) | 2022-08-10 |
HUE060597T2 (hu) | 2023-04-28 |
JP2020522517A (ja) | 2020-07-30 |
BR112019021703A2 (pt) | 2020-05-12 |
ES2927021T3 (es) | 2022-11-02 |
KR102607934B1 (ko) | 2023-12-01 |
US20180354968A1 (en) | 2018-12-13 |
IL271104A (en) | 2020-01-30 |
CN110770242A (zh) | 2020-02-07 |
EA202090014A1 (ru) | 2020-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47099A (fr) | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
MA47120A (fr) | Dérivés pyridine utilisés en tant qu'immunomodulateurs | |
MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
MA46091A (fr) | Composés biaryles utiles en tant qu'immunomodulateurs | |
MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine |